Home › Preeclampsia › NCT07229261
MitoQ to Improve Vascular Funciton in Preeclampsia
MitoQ (Mitoquinol Mesylate) to Ameliorate Vascular Function in Preeclampsia: a Novel Approach
Who can join
Ages 18 to 50 · Women
Full eligibility criteria
Inclusion Criteria: * Inpatient Cohort * pregnant patients with a clinical diagnosis of preeclampsia with severe features * gestational age between 23+0 and 33+0 weeks' gestation * singleton pregnancy * age 18-50 years old * No indication for immediate delivery (e.g. the patient and their physician team have planned expectant management of preeclampsia with severe features * Able to consent and follow a 2-step commend * English speaking * Outpatient Cohort * Pregnant patients with a clinical diagnosis of preeclampsia without severe features or gestational hypertension * gestational age between 23+0 and 34+0 weeks gestation * singleton pregnancy * age 18-50 years old * No indication for immediate delivery * Planned outpatient management of preeclampsia * Able to consent and follow a 2-step commend * English speaking Exclusion Criteria: * Unable to stand from chair without physical assistance from another person (able to use assistive device). * History of blood clots in the extremities or any condition in which compression of the thigh or transient ischemia is contraindicated (i.e., wounds in the leg). * Chronic lasting symptoms (\> 6 months) of severe COVID-19 (i.e., hospitalization) * History of head trauma or concussion within the past 6 months * Comorbid neurological disorder * Peripheral vascular disease * Diagnosed myocardial infarction or arrhythmia in the previous year * Resting SBP ≥180 mmHg or DBP ≥ 100 mmHg * Other significant medical condition likely to influence study or jeopardize safety as assessed by the Primary Investigator
About the study
Preeclampsia is a leading cause of maternal and neonatal morbidity and mortality. There is a lack of effective therapeutics for prevention or treatment. Our previous ex vivo work demonstrated that mitochondrial-antioxidants can reverse placental microvascular damage. Therefore, this study will evaluate whether MitoQ (Mitoquinol Mesylate, a mitochondrial-antioxidant) has the potential to restore vasodilation, improve placental function, and therefore promote pregnancy prolongation in patients with gestational hypertension (gHTN) and/or preeclampsia. This evaluation of clinical data, patient samples, and vascular function studies in patients with gHTN and/or preeclampsia could translate into a viable therapeutic option.
What is being tested
- Mitoquinol Mesylate (dietary supplement)
- Placebo (other)
Sponsor: Medical College of Wisconsin · Participants: 80 · Started: Mar 18, 2026
Contact the study team
- Jennifer McIntosh, D.O., M.S. · Phone: 14148059019
Official record on ClinicalTrials.gov — NCT07229261
Locations in the U.S.
| Wisconsin | Froedtert & the Medical College of Wisconsin, Milwaukee |
Conditions
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.